Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 7/20 | 0.56 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24955676 | 0.88 | MTOR (0.57) | MTORRAF1BRAFUSP2SMN1; SMN2 | |
| SCHEMBL31106959 | 0.85 | MTOR (0.52) | MTORPIK3R1PIK3CA | |
| SCHEMBL31106973 | 0.85 | MTOR (0.52) | MTORPIK3R1PIK3CA | |
| SCHEMBL441537 | 0.83 | MTOR (0.59) | MTORRAF1BRAFUSP2SMN1; SMN2 | |
| SCHEMBL22718259 | 0.81 | MTOR (0.59) | MTORRAF1BRAFUSP2SMN1; SMN2 | |
| SCHEMBL30202052 | 0.79 | MTOR (0.51) | MTORRAF1BRAFPIK3R1PIK3CA | |
| SCHEMBL24956799 | 0.79 | MTOR (0.51) | MTORRAF1BRAFPIK3R1PIK3CA | |
| SCHEMBL29899469 | 0.78 | MTOR (0.55) | MTORRAF1BRAFUSP2SMN1; SMN2 | |
| SCHEMBL1831342 | 0.77 | MTOR (0.73) | MTORRAF1BRAFPIK3CA | |
| SCHEMBL1835666 | 0.76 | MTOR (0.65) | MTORRAF1BRAFPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | MTOR 777/4885RAF1 3846/4885BRAF 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.